Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy.

ABSTRACT:

Importance

Current clinical and immunologic knowledge on cerebellar ataxia (CA) with glutamic acid decarboxylase 65 antibodies (GAD65-Abs) is based on case reports and small series with short-term follow-up data.

Objective

To report the symptoms, additional antibodies, prognostic factors, and long-term outcomes in a cohort of patients with CA and GAD65-Abs.

Design, setting, and participants

Retrospective cohort study and laboratory investigations at a center for autoimmune neurologic disorders among 34 patients with CA and GAD65-Abs, including 25 with long-term follow-up data (median, 5.4 years; interquartile range, 3.1-10.3 years).

Main outcomes and measures

Analysis of clinicoimmunologic features and predictors of response to immunotherapy. Immunochemistry on

SUBMITTER: Arino H 

PROVIDER: S-EPMC4841264 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature